#SFHS2608350AOrder of April 8, 2026, amending the list of reimbursable pharmaceutical specialities for social insured persons
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
The law expands coverage for certain pharmaceutical products used in young pediatric patients following organ transplants. It eliminates the co-payment requirement for these patients when using specific medications in combination with cyclosporine and corticosteroids. This change primarily impacts kidney, heart, and liver transplant recipients between ages 1 and 18.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Expanded reimbursement for specific drugs used post-organ transplants in pediatric patients.
- Elimination of co-payment requirements for these medications when used with cyclosporine and corticosteroids.
- Applies to kidney, heart, and liver transplant patients aged 1 to 18.
Obligations
What this law requires
Expand coverage of CELLCEPT (mycophénolate mofétil) in all three formulations (1 g/5 ml suspension, 250 mg capsules, 500 mg tablets) for pediatric organ transplant recipients when used in combination with cyclosporine and corticosteroids
Eliminate patient co-payment (participation de l'assuré) for CELLCEPT when prescribed for acute organ rejection prevention in eligible pediatric transplant patients, effective from the order publication date
Apply zero co-payment coverage specifically for pediatric kidney transplant recipients aged 1-2 years receiving CELLCEPT in combination with cyclosporine and corticosteroids
Apply zero co-payment coverage specifically for pediatric heart and liver transplant recipients aged 1-18 years receiving CELLCEPT in combination with cyclosporine and corticosteroids
Update the official list of reimbursable pharmaceutical specialities (liste des spécialités pharmaceutiques remboursables) as specified in Article L. 162-17 of the French Social Security Code to reflect the amendments in the attached Annex